The Holding Company for Pharmaceuticals, Chemicals and Medical Appliances aims to increase its consolidated revenues to EGP 18 billion during the fiscal year 2025/2026, with a targeted growth rate of 131% compared to the achieved in 2023/2024.
The company also aims to achieve net profits of EGP 3.4 billion, an increase of EGP 3431 TP3T, in addition to the development achieved in the market value of companies listed on the stock exchange.
This came in accordance with the Board of Directors' report, which was reviewed by Ashraf El-Khouly, Executive Managing Director of the Holding Company for Pharmaceuticals, during the company's general assembly. The report included the draft budget estimate for the current fiscal year.
Mohamed El-Shemy, Minister of the Public Business Sector, chaired the General Assembly of the Holding Company for Pharmaceuticals, Chemicals and Medical Appliances to approve the planning budget for the fiscal year 2025/2026. The meeting was attended by the Board of Directors, headed by Ahmed Hegazy, members of the General Assembly, and representatives of the Central Auditing Organization. Thus, the budgets of all holding companies and their subsidiaries for the fiscal year have been approved.
The Board of Directors' report included a presentation of major projects and promising investment opportunities, including the production of biological preparations, insulin and similar biological preparations, the manufacture of dry tablets for inhalation, and the production of active raw materials and hormones. It also includes projects in partnership with major international companies, including cooperation with the American company "Dawah" to produce and export a range of products, including: ampoules, nutritional supplements, sterile injections, and sterile ophthalmic preparations.
For his part, Mohamed Shemi affirmed that the pharmaceutical industry represents a vital pillar of health security and supports the national economy, emphasizing that its development and growth within the Ministry's affiliated companies is a strategic goal.
Shemi explained that the ministry is working to localize and deepen the pharmaceutical industry, transferring and applying the latest global manufacturing technologies, which will contribute to raising product quality and enhancing competitiveness in local, regional and international markets. He added that development projects include modernizing production lines and increasing manufacturing capacities, while strictly adhering to the highest standards of sustainability, quality and Good Manufacturing Practices (GMP), ensuring occupational safety and health at all workplaces, and making good use of available assets, capacities and resources.
He added that human resource development represents the primary driver for achieving these goals, through specialized training and qualification programs that support innovation and the development of scientific research, and by strengthening partnerships with the private sector, both locally and internationally, thus contributing to increased production and export capacities and opening new markets that support the competitiveness of national industry.
Shemi noted that the ministry prioritizes reforming the financial structures of its subsidiaries, ensuring sustainable profitability and providing the necessary resources for production expansion. He also highlighted the importance of updating organizational structures and developing management systems to keep pace with current requirements, while accelerating the implementation of the Enterprise Resource Planning (ERP) system to enhance operational efficiency and achieve precise control over resources and production.
The Minister also emphasized the importance of achieving integration between economic, social, and environmental dimensions to ensure comprehensive sustainability of the company's activities, while enhancing professional conduct, improving the work environment, and raising performance standards at various administrative and executive levels.
Concluding his remarks, he noted that the Ministry of Public Business Sector is confidently moving toward modernizing and restructuring its subsidiaries, achieving a balance between profitability and sustainability, thus enhancing Egypt's competitiveness regionally and globally. He noted that the Holding Company for Pharmaceuticals seeks to achieve regional leadership in the pharmaceutical industry and enhance Egypt's position as an advanced production and export center that meets the needs of the local market and expands into foreign markets.
